Gates-backed Exicure wraps 2016 with its first major collaboration and a plan for the year ahead
Exicure has crossed a few key items off the to-do list that dominates the existence of every upstart biotech. And it’s wrapping up 2016 with a rite of passage that helps position it for a New Year filled with pipeline building plans and new partnership hunts.
This morning the Chicago-based biotech is announcing that it has completed its first industry collaboration, passing along its lead drug that has just successfully navigated a small proof-of-concept study in psoriasis. Purdue Pharma is stepping in with a pact — worth up to $790 million if all the cards turn in its favor — that will give it control of a Phase II-ready psoriasis drug along with three more programs to be decided later.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.